Sai Life Sciences Q1 FY27 results: dates, estimates 2026

Stock snapshot as results season nears

Sai Life Sciences (NSE: SAILIFE, BSE: 544306) is in focus ahead of its Q1 FY27 earnings schedule. The stock was reported around ₹1,257.3, with a BSE print of ₹1,260 up 0.32% on July 3 at 4:01 PM. The day’s range on that snapshot showed a high of ₹1,260 and a low of ₹1,237.5. The 52-week low mentioned is ₹776.2. Alongside price action, the market capitalisation cited in the data is ₹26,690.72079168 crore.

Board meeting fixed for August 6, 2026

The company has informed exchanges that its Board of Directors will meet on August 6, 2026. The stated agenda is to consider and approve unaudited financial results for the quarter ended June 30, 2026. The approval will cover both standalone and consolidated numbers. This places Sai Life Sciences on the formal results calendar for Q1 FY27.

Earnings call on August 7 with top management

Sai Life Sciences has also scheduled an earnings conference call for August 7, 2026, from 4:00 PM to 5:00 PM IST. The call is set to feature Managing Director and CEO Krishna Kanumuri and Director and CFO Siva Chittor. The stated purpose is to discuss the unaudited financial results for the quarter ended June 30, 2026, and provide management commentary. The disclosure cites SEBI Regulation 30 as the compliance basis for the announcement.

Conference call access details

Investors were provided dial-in details for the August 7 call. The document lists India dial-in numbers as +91 22 6280 1107 and +91 22 7115 8008. International access points include USA: 18667462133 and UK: 08081011573. The company filed the schedule with NSE and BSE on July 30, 2026, positioning the call as a structured update for shareholders and analysts.

Trading window closure around results

The company stated that its trading window was closed from July 1, 2026 to August 8, 2026. The closure applies to directors, officials, and designated persons. The stated intent is to prevent insider trading around the results process, aligning with standard listed-company controls during sensitive periods.

What the recent quarterly trend shows (FY26 quarterly run)

A quarterly table in the data lists net sales, operating profit, and adjusted EPS across five quarters ending March 2026. Net sales moved from ₹567.01 crore (Mar 2025) to ₹483.04 crore (Jun 2025), then ₹526.67 crore (Sep 2025) and ₹549.18 crore (Dec 2025), before rising to ₹594.34 crore (Mar 2026). Operating profit in the same sequence is ₹153.9 crore, ₹113 crore, ₹139.85 crore, ₹178.97 crore, and ₹168.14 crore. Adjusted EPS (₹) is listed as 4.32, 2.8, 3.95, 4.62, and 4.84.

Reference point: Q1 FY26 reported performance

The article text also includes Sai Life Sciences’ Q1 FY26 performance snapshot. Revenue from operations for Q1 FY26 was reported at ₹496 crore, compared with ₹280 crore in Q1 FY25, described as 77% growth led primarily by the CDMO segment. EBITDA was reported at ₹125 crore for Q1 FY26 versus ₹31 crore in Q1 FY25, described as a 305% increase. The EBITDA margin was stated to have expanded by 14% year-on-year to 25% in Q1 FY26. Profit after tax (PAT) for Q1 FY26 was reported at ₹60 crore, and capex during the quarter was stated at ₹134 crore.

Q1 FY27 estimates and what they are based on

The dataset includes a preview framework that references a trailing-growth approach. It cites a Q1 FY26 base of ₹506 crore revenue and ₹60 crore net profit for the purpose of building estimates, and also points to Q4 FY26 base metrics of ₹618 crore revenue and ₹104 crore net profit. Based on that method, the Q1 FY27 estimated revenue range cited is ₹494-568 crore, with Q1 FY26 actual revenue in the table shown as ₹506 crore and an indicated year-on-year growth of +4.8%. For PAT, the estimated range is ₹63-80 crore against Q1 FY26 actual ₹60 crore with an indicated year-on-year growth of +18.1%.

The same section notes a 12-month target range of ₹1,250-1,413 (Uniresearch estimate) and states Sai Life Sciences was trading around ₹1,252 when that preview was framed. Another snapshot in the text references the stock trading at ₹1,252 against a market capitalisation of ₹26,284 crore and a price-to-earnings multiple of 75.3.

Other investor engagement mentioned

Separately, the text notes a group meeting scheduled with Goldman Sachs analysts and investors in Hyderabad on June 11, 2026. While no outcome is stated, the mention indicates continued investor interaction ahead of the Q1 FY27 reporting window.

Market impact: what investors are tracking now

From a market standpoint, the key near-term driver is the August 6 board meeting that is expected to approve Q1 FY27 unaudited results, followed by the August 7 earnings call where investors typically look for management commentary on demand, capacity, margins, and capital spending. The trading-window closure through August 8 provides a compliance frame around the announcement cycle. Investors are also benchmarking near-term performance against the Q1 FY26 reported numbers of ₹496 crore revenue, ₹125 crore EBITDA, and ₹60 crore PAT, and against the quarterly trend through March 2026. Finally, the published estimate ranges (₹494-568 crore revenue and ₹63-80 crore PAT) and the stated target band (₹1,250-1,413) set reference points that market participants may use to compare reported outcomes when Q1 FY27 numbers are released.

Conclusion

Sai Life Sciences has put clear dates on its Q1 FY27 reporting process, with the board meeting scheduled for August 6, 2026 and the earnings call on August 7, 2026. The next confirmed milestone is management’s commentary during the call, following the approval of the unaudited standalone and consolidated results for the quarter ended June 30, 2026.